New cocktail of drugs tested for Tough-to-Treat lymphoma

NCT ID NCT02436707

Ongoing Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinexor, and researchers will compare how well they work against the usual treatment. The main goal is to see if these new combinations can shrink or eliminate the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor
What this could lead to: If successful, this could point toward more effective treatment options for patients with aggressive B-cell lymphoma that has returned or not responded to prior therapy.
What could go wrong: This is an early-phase trial with a small number of participants (129). The new combinations may not work better than standard treatment and could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma lymphoma lymphoplasmacytic lymphoma MALT lymphoma marginal zone lymphoma primary mediastinal large B-cell lymphoma T-cell/histiocyte rich large B cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA

Contacts and locations

Locations

Allan Blair Cancer Centre

Regina, Saskatchewan, S4T 7T1, Canada
Arthur J.E. Child Comprehensive Cancer Centre

Calgary, Alberta, T2N 5G2, Canada
BCCA - Vancouver

Vancouver, British Columbia, V5Z 4E6, Canada
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)

Québec, Quebec, G1J 1Z4, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal

Montreal, Quebec, H2X 3E4, Canada
CancerCare Manitoba

Winnipeg, Manitoba, R3E 0V9, Canada
Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada
Kingston Health Sciences Centre

Kingston, Ontario, K7L 2V7, Canada
Ottawa Hospital Research Institute

Ottawa, Ontario, K1H 8L6, Canada
QEII Health Sciences Centre

Halifax, Nova Scotia, B3H 1V7, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.